ClinicalTrials.gov
public full text
Public Domain
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone
Giant cell tumor of bone (GCTb) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of relapsed or refractoriness GCT with denosumab and to assess adverse effect profile and recurrence rate.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effects of Denosumab on Bone Fusion in Osteoporotic Patients After Lumbar Fusion#1059113
- Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer#1171238
- Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation.#439024
- Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant#432898
- Data for "In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation"#280735
Record · ID 826669
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive